Antiaging medicine and mild cognitive impairment: Practice and policy issues for geriatrics

Journal of the American Geriatrics Society

Volumn 53, Issue 8, 2005, Pages 1417-1422

  Whitehouse, Peter J ^a   Juengst, Eric T ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Antiaging; Geriatrics; Mild cognitive impairment

Indexed keywords

ALPHA TOCOPHEROL;

AGING; ALZHEIMER DISEASE; ANTIAGING MEDICINE; BRAIN MATURATION; COGNITIVE DEFECT; DISEASE COURSE; ECONOMICS; GERIATRICS; HEALTH CARE POLICY; HUMAN; LONGEVITY; MEDICINE; PHILOSOPHY; POLITICS; PRACTICE GUIDELINE; REVIEW; AGED; HEALTH CARE AND PUBLIC HEALTH; PHYSIOLOGY; STANDARD;

HEALTH CARE AND PUBLIC HEALTH;

AGED; AGING; COGNITION DISORDERS; GERIATRICS; HUMANS; PHILOSOPHY, MEDICAL;

EID: 25144503343     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2005.53411.x     Document Type: Review

References (44)

1. Hall SS. Merchants of Immortality. New York: Houghton-Mifflin, 2003.
2. Rothman SM, Rothman DJ. The Pursuit of Perfection: The Promise and Perils of Medical Enhancement. New York: Pantheon Publishing Co., 2003.
3. Petersen RC, Smith GE, Waring SC et al. Aging, memory and mild cognitive impairment. Int Psychogeriatr 1997;9(Suppl 1):65-69.
4. Ritchie K, Touchon J. Mild cognitive impairment. Conceptual basis and current nosological status. Lancet 2000;355:225-228.
5. Bozoki A, Giordiani B, Heidebrink J et al. Mild cognitive impairment predicts dementia in non-demented elderly persons with memory loss. Arch Neurol 2001;58:411-416.
6. Whitehouse P. MCI and Alzheimer's disease: Different conditions or diagnostic confusion? Psychiatr Times 2004;2:87-88.
7. Petersen RC, Stevens JC, Ganguli M et al. Practice parameter. Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-1142.
8. Whitehouse PJ, Moody HR. Mild cognitive impairment. A hardening of the categories. Demential in press.
9. Whitehouse PJ. The future of mild cognitive impairment. Fifth Issue. MCI Forum: HELP Medical Publications, France, 2004.
10. Mehlman MM, Binstock RH, Juengst EJ et al. Antiaging medicine: Can consumers be better protected? Gerontologist 2004;44:304-310.
11. American Geriatrics Society. The Use of Drugs of Questionable Efficacy in the Elderly: Position Statement [on-line]. Available at www.americangeriatrics. org/products/positionpapers/useofdrugs.shtml. Accessed March 29, 2005.
12. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-1222.
13. American Academy of Anti-Aging Medicine Website. Available at www. world-health.net/a4m.html. Accessed March 29, 2005.
14. Fukuyama F. Our Posthuman Future. Consequences of the Biotechnology Revolution. New York: Profile Books, 2003.
15. Olshansky SJ, Hayflick L, Carnes B. Position statement of human aging. J Gerontol A Biol Sci Med Sci 2002;57A:B292-B297.
16. Binstock RH. The war on antiaging medicine. Gerontologist 2003;43:4-14.
17. Kirkland J. The biology of senescence: Potential for prevention of disease. Clin Geriatr Med 2002;18:383-405.
18. Juengst ET, Binstock RH, Mehlman M et al. Biogerontology, 'antiaging medicine' and the challenges of human enhancement. Hastings Cent Rep 2003;33:21-30.
19. Rowe JW, Kahn RL. Successful Aging. New York: Pantheon Books, 1997.
20. Shelton DL. Dipping into the fountain of youth. American Medical News December 4, 2000, pp 3-5.
21. Hayflick L. Anti-aging medicine. hype, hope and reality. Generations 2002;24: 20-26.
22. Caplan A. An unnatural process: Why it is not inherently wrong to seek a cure for aging. In: Post SG, Binstock RH, eds. The Fountain of Youth. Cultural, Scientific and Ethical Perspectives on a Biomedical Goal. New York: Oxford University Press, 2004, pp 271-286.
23. Forbes WF, Thompson ME. Age-related diseases and normal aging: The nature of the relationship. J Clin Epidemiol 1990;43:191-193.
24. Logothetis ML. Disease or development? Women's perceptions of menopause. In: Callahan J, ed. Menopause. A Midlife Passage. Bloomington: Indiana University Press, 1993, pp 123-135.
25. Crook T, Bartus RT, Ferris SH et al. Age-associated memory impairment. Proposed diagnostic criteria and measures of clinical change - Report of a National Institute of Mental Health Work Group. Dev Neuropsychol 1986; 2:261-276.
26. Levy R. Aging-associated cognitive decline. Working Party of International Psychogeriatric Association in collaboration of the World Health Organization. Int Psychogeriatr 1994;6:63-68.
27. Rivas-Vazquez R, Mendez C, Rey G et al. Mild cognitive impairment. A new neurophysiological and pharmacological target. Arch Clin Neuropsychol 2004;19:11-27.
28. Fries JF. Aging, natural death and the compression of morbidity. N Engl J Med 1980;303:130-136.
29. Dubois B. Prodromal Alzheimer's disease: A more useful concept than mild cognitive impairment? Curr Opin Neurol 2000;13:367-369.
30. Morris JC, Storandt M, Miller P et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58:397-405.
31. Davis HS, Rockwood K. Conceptualization of mild cognitive impairment: A review. Int J Geriatr Psychiatry 2004;19:313-319.
32. Whitehouse PJ. Classifications of the dementias. Lancet 2003;361:1227.
33. Richie K, Lovestone S. The dementias. Lancet 2002;360:1759-1766.
34. Yesavage JA, Mumenthaler MS, Taylor JL et al. Donepezil and flight simulator performance: Effects on retention of complex skills. Neurology 2002;59: 123-125.
35. Gaines AD, Whitehouse PJ. Building a mystery. Alzheimer disease, MCI and beyond. Philos Psychiatry in press.
36. Whitehouse PJ. Review. Losing my mind. In: DeBaggio T, ed. Losing My Mind: An Intimate Look at Life with Alzheimer's. N Engl J Med 2002;347:861.
37. Miller R. Extending life. Scientific prospects and political obstacles. Milbank Q 2002;80:155-174.
38. Action Plan for Aging Research: Strategic Plan for Fiscal Years 2001-2005. Washington, DC: National Institute on Aging, U.S. Department of Health and Human Services, 2000.
39. American Geriatrics Society [on-line]. Available at www. americangeriatrics.org.
40. Juengst ET, Ponsaran R. Normal aging, disease prevention, and medical ethics. Public Pol Aging Rep 2004, 14-18.
41. Juengst ET. Concepts of disease after the Human Genome Project. In: Wear S, Bono J, Logue G, eds. Ethical Issues in Health Care on the Frontiers of the Twenty-First Century. Dordrecht, Netherlands: Kluwer Academic Publishers, 2000, pp 125-152.
42. Nelkin D, Tancredi L. Dangerous Diagnostics. The Social Power of Biological Information. New York: Basic Books, 1989.
43. Post S. Preventing schizophrenia and Alzheimer disease: Comparative ethics. Schizophr Res 2001;51:103-108.
44. De Grey A. An engineer's approach to developing real antiaging medicine. In: Post SG, Binstock RH, eds. The Fountain of Youth: Cultural, Scientific and Ethical Perspectives on a Biomedical Goal. New York: Oxford University Press, 2004, pp 249-267.